Patrick M. Boland

4.6k total citations
110 papers, 2.1k citations indexed

About

Patrick M. Boland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Patrick M. Boland has authored 110 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 28 papers in Pathology and Forensic Medicine. Recurrent topics in Patrick M. Boland's work include Colorectal Cancer Treatments and Studies (45 papers), Genetic factors in colorectal cancer (24 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Patrick M. Boland is often cited by papers focused on Colorectal Cancer Treatments and Studies (45 papers), Genetic factors in colorectal cancer (24 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Patrick M. Boland collaborates with scholars based in United States, Australia and Spain. Patrick M. Boland's co-authors include C. Richard Boland, Matthew B. Yurgelun, Tanios Bekaii‐Saab, Marwan Fakih, Jennifer Wu, Fang‐Shu Ou, Kristopher Attwood, Sabina Sandigursky, Steven Nurkin and David Kleinfeld and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick M. Boland

104 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick M. Boland United States	26	1.3k	555	423	374	367	110	2.1k
Ji‐Won Kim South Korea	23	945 0.8×	244 0.4×	525 1.2×	588 1.6×	426 1.2×	155	2.1k
Adam J. Olszewski United States	28	1.3k 1.1×	1.3k 2.4×	246 0.6×	539 1.4×	240 0.7×	212	3.1k
Shangli Cai China	21	990 0.8×	158 0.3×	548 1.3×	615 1.6×	197 0.5×	110	1.9k
Bing Wei China	22	651 0.5×	426 0.8×	464 1.1×	335 0.9×	221 0.6×	121	1.7k
Athena Matakidou United Kingdom	21	833 0.7×	368 0.7×	751 1.8×	1.6k 4.4×	223 0.6×	39	2.9k
Scott K. Kuwada United States	24	554 0.4×	309 0.6×	203 0.5×	535 1.4×	442 1.2×	67	1.7k
Shuichi Mitsunaga Japan	28	1.0k 0.8×	242 0.4×	347 0.8×	544 1.5×	473 1.3×	125	2.5k
István Kenessey Hungary	25	766 0.6×	140 0.3×	322 0.8×	769 2.1×	385 1.0×	118	2.0k
Raphaël Maréchal Belgium	22	1.5k 1.2×	180 0.3×	403 1.0×	497 1.3×	550 1.5×	63	2.3k
Jean‐Christophe Saurin France	35	1.1k 0.9×	800 1.4×	1.2k 2.9×	631 1.7×	1.2k 3.4×	155	3.4k

Countries citing papers authored by Patrick M. Boland

Since Specialization

Citations

This map shows the geographic impact of Patrick M. Boland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Boland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Boland more than expected).

Fields of papers citing papers by Patrick M. Boland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Boland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Boland. The network helps show where Patrick M. Boland may publish in the future.

Co-authorship network of co-authors of Patrick M. Boland

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Boland. A scholar is included among the top collaborators of Patrick M. Boland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Boland. Patrick M. Boland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Handorf, Elizabeth A., Benjamin Bates, David G. Brauer, et al.. (2025). Estimating the Survival Impact of Curative-Intent Liver Therapies for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology. 32(9). 6263–6271.

Kennedy, Timothy J., Mihir M. Shah, Rafi Kabarriti, et al.. (2025). Phase II preoperative pembrolizumab for MSI high or MSS/PD-L1 gastric cancer followed by surgery and adjuvant therapy with pembrolizumab (NCT03257163): Results of a multicenter study.. Journal of Clinical Oncology. 43(4_suppl). 441–441. 1 indexed citations

Boland, Patrick M., Heinz‐Josef Lenz, Kristen K. Ciombor, et al.. (2024). A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs. 43(1). 60–68. 2 indexed citations

Le, Dung T., Luis A. Díaz, Tae Won Kim, et al.. (2023). Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. 186. 185–195. 46 indexed citations

Mohammed, Turab, Rohit Gosain, Navpreet Rana, et al.. (2023). Geographic and Demographic Disparities in Colorectal Cancer: A National Cancer Database Analysis. Hematology/Oncology and Stem Cell Therapy. 16(3). 262–271. 2 indexed citations

Bhurosy, Trishnee, et al.. (2022). Underdiagnosis of iron deficiency anemia among patients with colorectal cancer: an examination of electronic medical records. BMC Cancer. 22(1). 435–435. 10 indexed citations

Pedersen, Katrina S., Nathan R. Foster, Michael J. Overman, et al.. (2021). ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clinical Cancer Research. 27(13). 3641–3648. 38 indexed citations

Jatoi, Aminah, Fang‐Shu Ou, Daniel H. Ahn, et al.. (2021). Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. The Oncologist. 26(7). 610–618. 5 indexed citations

Boland, C. Richard, et al.. (2021). Managing gastric cancer risk in lynch syndrome: controversies and recommendations. Familial Cancer. 21(1). 75–78. 12 indexed citations

10.

Catenacci, Daniel V.T., Byoung Yong Shim, S.T. Kim, et al.. (2021). 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A. Annals of Oncology. 32. S1043–S1044. 13 indexed citations

11.

Malhotra, Usha, Sarbajit Mukherjee, Christos Fountzilas, et al.. (2019). Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates. Molecular Cancer Therapeutics. 19(1). 304–311. 5 indexed citations

12.

Wainberg, Zev A., Patrick M. Boland, Christopher H. Lieu, et al.. (2019). A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Annals of Oncology. 30. iv123–iv123. 3 indexed citations

13.

Mukherjee, Sarbajit, Christos Fountzilas, Patrick M. Boland, et al.. (2019). Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Targeted Oncology. 15(1). 85–92. 4 indexed citations

14.

Boland, Patrick M., Matthew B. Yurgelun, & C. Richard Boland. (2018). Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA A Cancer Journal for Clinicians. 68(3). 217–231. 111 indexed citations

15.

Gabriel, Emmanuel, Kristopher Attwood, Eisar Al‐Sukhni, et al.. (2018). Age-related rates of colorectal cancer and the factors associated with overall survival. Journal of Gastrointestinal Oncology. 9(1). 96–110. 41 indexed citations

16.

Gabriel, Emmanuel, Kristopher Attwood, Wen Wee, et al.. (2017). Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation. Clinical Colorectal Cancer. 16(4). 300–307. 26 indexed citations

17.

Eng, Cathy, Marwan Fakih, Manik Amin, et al.. (2017). P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer. Annals of Oncology. 28. v181–v182. 4 indexed citations

18.

Vijayvergia, Namrata, Patrick M. Boland, Elizabeth A. Handorf, et al.. (2016). Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. British Journal of Cancer. 115(5). 564–570. 80 indexed citations

19.

Perkins, James D., Patrick M. Boland, Steven J. Cohen, et al.. (2014). Successful Imatinib Therapy for Neuroendocrine Carcinoma With ActivatingKITMutation: A Case Study. Journal of the National Comprehensive Cancer Network. 12(6). 847–852. 13 indexed citations

20.

White, Mitchell R., Patrick M. Boland, Tesfaldet Tecle, et al.. (2009). Enhancement of Antiviral Activity of Collectin Trimers through Cross-Linking and Mutagenesis of the Carbohydrate Recognition Domain. Journal of Innate Immunity. 2(3). 267–279. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact